HNC1058 / Henovcom - LARVOL DELTA

Autotaxin inhibitors: an updated patent review (2021-present). (PubMed, Expert Opin Ther Pat) - "Currently, beyond the Phase II candidates PAT409 and HW021199, ATX inhibitors FTP-198 and HNC1058 have entered Phase I clinical trials for pulmonary fibrosis, while IOA-289 and HNC664 have advanced to clinical studies for solid tumors, underscoring the immense therapeutic potential of ATX. Although the identification of type V and VI ATX inhibitors has broadened the design landscape, most emerging entities since 2020 remain analogs of GLPG1690 and PAT409, presumably being attributed to the unavailable data of most clinical candidates, and despite the absence of approved drugs, the continued evolution of drug design strategies and application of novel technologies would further facilitate the discovery of ATX candidates, ultimately offering more therapeutic options for patients."

Journal • Review • Immunology • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058 (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Guangzhou Henovcom Bioscience Co. Ltd. | Enrolling by invitation ➔ Completed

Trial completion • Idiopathic Pulmonary Fibrosis

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058 (clinicaltrials.gov) - P1 | N=32 | Enrolling by invitation | Sponsor: Guangzhou Henovcom Bioscience Co. Ltd. | Not yet recruiting ➔ Enrolling by invitation | Trial completion date: Sep 2023 ➔ Mar 2024 | Trial primary completion date: Aug 2023 ➔ Mar 2024

Enrollment open • Trial completion date • Trial primary completion date • Idiopathic Pulmonary Fibrosis

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058 (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Guangzhou Henovcom Bioscience Co. Ltd.

New P1 trial